Fluorouracil and Dose-Dense Chemotherapy in Adjuvant Treatment of Patient with Early-Stage Breast Cancer: an Open-Label, 2 x 2 Factorial, Randomised Phase III Trial

被引：0
|
作者：
Colle, E. [1 ]
Besse, B. [2 ]
机构：
[1] AERIO, Paris, France
[2] Gustave Roussy, F-94800 Villejuif, France
来源：
ONCOLOGIE | 2015年 / 17卷 / 7-8期
关键词：
METAANALYSIS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：330 / 332
页数：3
相关论文
共 14 条
  • [1] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial
    Del Mastro, Lucia y
    De Placido, Sabino
    Bruzzi, Paolo
    De Laurentiis, Michele
    Boni, Corrado
    Cavazzini, Giovanna
    Durando, Antonio
    Turletti, Anna
    Nistico, Cecilia
    Valle, Enrichetta
    Garrone, Ornella
    Puglisi, Fabio
    Montemurro, Filippo
    Barni, Sandro
    Ardizzoni, Andrea
    Gamucci, Teresa
    Colantuoni, Giuseppe
    Giuliano, Mario
    Gravina, Adriano
    Papaldo, Paola
    Bighin, Claudia
    Bisagni, Giancarlo
    Forestieri, Valeria
    Cognetti, Francesco
    LANCET, 2015, 385 (9980): : 1863 - 1872
  • [2] Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies
    Lambertini, Matteo
    Ceppi, Marcello
    Cognetti, Francesco
    Cavazzini, Giovanna
    De Laurentiis, Michele
    De Placido, Sabino
    Michelotti, Andrea
    Bisagni, Giancarlo
    Durando, Antonio
    Valle, Enrichetta
    Scotto, Tiziana
    De Censi, Andrea
    Turletti, Anna
    Benasso, Marco
    Barni, Sandro
    Montemurro, Filippo
    Puglisi, Fabio
    Levaggi, Alessia
    Giraudi, Sara
    Bighin, Claudia
    Bruzzi, Paolo
    Del Mastro, Lucia
    EUROPEAN JOURNAL OF CANCER, 2017, 71 : 34 - 42
  • [3] Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients
    Reinisch, Mattea
    Gluz, Oleg
    Ataseven, Beyhan
    Blohmer, Jens-Uwe
    Budner, Marek
    Dittmer-Grabowski, Christine
    Kohls, Andreas
    Krocker, Jutta
    Kuemmel, Aylin
    Hagemann, Friederike
    Rueland, Anna
    Traut, Alexander
    Kuemmel, Sherko
    BREAST CARE, 2019, 14 (03) : 159 - 164
  • [4] Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
    Poggio, F.
    Blondeaux, E.
    Tagliamento, M.
    Perachino, M.
    Nardin, S.
    Conte, B.
    Giuliano, M.
    Arpino, G.
    De Laurentiis, M.
    Gravina, A.
    Bisagni, G.
    Rimanti, A.
    Turletti, A.
    Nistico, C.
    Magnolfi, E.
    Gasparro, S.
    Fabi, A.
    Garrone, O.
    Alicicco, M. G.
    Urracci, Y.
    Poletti, P.
    Correale, P.
    Molinelli, C.
    Fozza, A.
    Puglisi, F.
    Colantuoni, G.
    Fregatti, P.
    Boni, L.
    Lambertini, M.
    Del Mastro, L.
    ESMO OPEN, 2024, 9 (08)
  • [5] Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
    Behringer, Karolin
    Goergen, Helen
    Hitz, Felicitas
    Zijlstra, Josee M.
    Greil, Richard
    Markova, Jana
    Sasse, Stephanie
    Fuchs, Michael
    Topp, Max S.
    Soekler, Martin
    Mathas, Stephan
    Meissner, Julia
    Wilhelm, Martin
    Koch, Peter
    Lindemann, Hans-Walter
    Schalk, Enrico
    Semrau, Robert
    Kriz, Jan
    Vieler, Tom
    Bentz, Martin
    Lange, Elisabeth
    Mahlberg, Rolf
    Hassler, Andre
    Vogelhuber, Martin
    Hahn, Dennis
    Mezger, Joerg
    Krause, Stefan W.
    Skoetz, Nicole
    Boell, Boris
    von Tresckow, Bastian
    Diehl, Volker
    Hallek, Michael
    Borchmann, Peter
    Stein, Harald
    Eich, Hans
    Engert, Andreas
    LANCET, 2015, 385 (9976): : 1418 - 1427
  • [6] Connected device and therapeutic patient education to promote physical activity among women with localised breast cancer (DISCO trial): protocol for a multicentre 2x2 factorial randomised controlled trial
    Touillaud, Marina
    Fournier, Baptiste
    Perol, Olivia
    Delrieu, Lidia
    Maire, Aurelia
    Belladame, Elodie
    Perol, David
    Perrier, Lionel
    Preau, Marie
    Leroy, Tanguy
    Fassier, Jean-Baptiste
    Fillol, Florie
    Pascal, Sebastien
    Durand, Thierry
    Fervers, Beatrice
    BMJ OPEN, 2021, 11 (09):
  • [7] Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
    Bahadoer, Renu R.
    Dijkstra, Esmee A.
    van Etten, Boudewijn
    Marijnen, Corrie A. M.
    Putter, Hein
    Kranenbarg, Elma Meershoek-Klein
    Roodvoets, Annet G. H.
    Nagtegaal, Iris D.
    Beets-Tan, Regina G. H.
    Blomqvist, Lennart K.
    Fokstuen, Tone
    ten Tije, Albert J.
    Capdevila, Jaume
    Hendriks, Mathijs P.
    Edhemovic, Ibrahim
    Cervantes, Andres
    Nilsson, Per J.
    Glimelius, Bengt
    van de Velde, Cornelis J. H.
    Hospers, Geke A. P.
    LANCET ONCOLOGY, 2021, 22 (01): : 29 - 42
  • [8] Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
    Moebus, V.
    Jackisch, C.
    Luck, H. J.
    du Bois, A.
    Thomssen, C.
    Kuhn, W.
    Nitz, U.
    Schneeweiss, A.
    Huober, J.
    Harbeck, N.
    von Minckwitz, G.
    Runnebaum, I. B.
    Hinke, A.
    Konecny, G. E.
    Untch, M.
    Kurbacher, C.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 178 - 185
  • [9] Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
    Grinsztejn, Beatriz
    De Castro, Nathalie
    Arnold, Vincent
    Veloso, Valdilea G.
    Morgado, Mariza
    Pilotto, Jose Henrique
    Brites, Carlos
    Madruga, Jose Valdez
    Barcellos, Nemora Tregnago
    Santos, Breno Riegel
    Vorsatz, Carla
    Fagard, Catherine
    Santini-Oliveira, Marina
    Patey, Olivier
    Delaugerre, Constance
    Chene, Genevieve
    Molina, Jean-Michel
    LANCET INFECTIOUS DISEASES, 2014, 14 (06): : 459 - 467
  • [10] PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis
    Untch, M.
    von Minckwitz, G.
    Konecny, G. E.
    Conrad, U.
    Fett, W.
    Kurzeder, C.
    Lueck, H. -J.
    Stickeler, E.
    Urbaczyk, H.
    Liedtke, B.
    Beckmann, M. W.
    Salat, C.
    Harbeck, N.
    Mueller, V.
    Schmidt, M.
    Hasmueller, S.
    Lenhard, M.
    Nekljudova, V.
    Lebeau, A.
    Loibl, S.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 1999 - 2006
12